18.44

1.95% -0.33

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $18.44, with a volume of 96,515. It is down -1.95% in the last 24 hours and down -12.49% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$18.77

Open:

$18.75

24h Volume:

96,515

Relative Volume:

0.12

Market Cap:

$561.14M

Revenue:

Net Income/Loss:

$-168.05M

P/E Ratio:

-3.5945

EPS:

-5.13

Net Cash Flow:

$-146.15M

1W Performance:

-0.14%

1M Performance:

-12.49%

6M Performance:

+27.28%

1Y Performance:

+60.73%

1-Day Range:

$18.30

$19.13

1-Week Range:

$18.30

$19.94

52-Week Range:

$9.12

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1119)

Industry

Biotechnology (624)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

KROS's Discussions on Twitter

Compare KROS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KROS Keros Therapeutics Inc	18.42	571.85M	0	-168.05M	-146.15M	-5.13
VRTX Vertex Pharmaceuticals Inc	473.10	120.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	768.45	80.15B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	865.92	51.56B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	359.09	47.74B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	336.12	37.38B	4.98B	69.59M	525.67M	0.5197

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-16-24	Reiterated	Oppenheimer	Outperform
Dec-13-24	Reiterated	H.C. Wainwright	Buy
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy
Jun-25-24	Initiated	Oppenheimer	Outperform
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

08:23 AM

Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - Zacks Investment Research

08:23 AM

Jan 26, 2026

Portfolio Shifts: Can NECB benefit from deglobalizationJuly 2025 Reactions & Community Driven Trade Alerts - baoquankhu1.vn

Jan 26, 2026

Market Wrap: What is the next catalyst for Keros Therapeutics IncAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn

Jan 26, 2026

Fund Flows: Does Keros Therapeutics Inc stock reflect fundamentalsWeekly Profit Report & Smart Investment Allocation Tips - baoquankhu1.vn

Jan 25, 2026

Jan 23, 2026

Is Keros Therapeutics Inc. backed by strong institutional buyingQuarterly Trade Summary & AI Driven Price Predictions - mfd.ru

Jan 23, 2026

JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Nasdaq

Jan 23, 2026

Jan 22, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Jan 22, 2026

Jan 21, 2026

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz

Jan 21, 2026

Jan 17, 2026

Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - sharewise.com

Jan 17, 2026

Jan 16, 2026

Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz

Jan 16, 2026

Jan 15, 2026

KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - sharewise.com

Jan 15, 2026

CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz

Jan 15, 2026

(KROS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Jan 15, 2026

Jan 14, 2026

TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz

Jan 14, 2026

Downgrade Watch: What’s the RSI of Keros Therapeutics Inc. stock2025 Performance Recap & Long-Term Safe Investment Plans - baoquankhu1.vn

Jan 14, 2026

TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz

Jan 14, 2026

Aug Technicals: Is Keros Therapeutics Inc likely to announce a buybackJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn

Jan 14, 2026

Jan 13, 2026

History Review: What are Keros Therapeutics Incs technical support levelsJuly 2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn

Jan 13, 2026

BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises - Zacks Investment Research

Jan 13, 2026

Jan 12, 2026

MACD Signal: Whats the fair value of Keros Therapeutics Inc stock2025 Key Highlights & Free Daily Entry Point Trade Alerts - baoquankhu1.vn

Jan 12, 2026

INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced - Finviz

Jan 12, 2026

Jan 09, 2026